Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine Continuous Infusion for Pain in Severe Burn Patients
NCT02860117Phase 3
Key facts
- Status
- Withdrawn
- Start
- Jan 2018
- Primary completion
- Jan 2019
- Countries
- 1
- Sponsor
- Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
- Modality
- Small Molecules
- Drugs
- ketamine
01
Overview
Phase 3, randomised, double-blind trial comparing Ketamine with Placebo (2 arms). Primary endpoint: Opioid consumption at 10 days. Planned start Jan 2018; status: withdrawn.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Ketamine
Ketamine continuous infusion 0.2mg/kg/h
Placebo
Placebo continuous infusion
03
Who it enrols
Adult patients (18-60 years) with burns covering >= 25% of body area, ASA I-II, hemodynamically stable, and GCS 15. Excludes patients with chronic pain, chronic analgesic use, or ASA III+.
04
Endpoints
Primary
Opioid consumption
Secondary
Side effects questionnaire
Beyond the preview
Go deeper on NCT02860117.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02860117.